.webp)
Key takeaways:
- GLP-1 receptor agonists are rapidly reshaping obesity treatment and are increasingly used in patients with disorders of gut-brain interaction.
- The gastrointestinal effects of these medications don't always align with standard weight-loss pathways, adding complexity for patients with DGBIs.
- In the discussion, gastroenterologist Dr. Samuel Muench offers practical guidance for clinicians managing these complex patients where obesity care and gut-brain disorders overlap.
GLP-1 receptor agonists are rapidly reshaping obesity treatment and are increasingly used in patients with disorders of the brain-gut interaction (DGBIs). Yet their gastrointestinal effects don’t always align with standard weight-loss pathways.
Watch the discussion led by gastroenteerologist Dr. Samuel Muench for practical guideance on managing these complex patients.
.webp)